Expert Review of Anti-Infective Therapy

Papers
(The H4-Index of Expert Review of Anti-Infective Therapy is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
The efficacy and safety of complement C5a inhibitors for patients with severe COVID-19: a systematic review and meta-analysis116
Challenges in preserving antibiotic effectiveness: time for a novel approach87
Sulbactam-durlobactam for the treatment of Acinetobacter baumannii-calcoaceticus complex57
Neonatal ocular prophylaxis in the United States: is it still necessary?53
Part 1: Understanding the role of Malassezia spp. in skin disorders: Malassezia yeasts as commensal or pathogenic organisms of human and a52
A narrative review on drug development for the management of antimicrobial- resistant infection crisis in Japan: the past, present, and future47
Visceral leishmaniasis elimination in India: progress and the road ahead47
Optic and peripheral neuropathy associated with short and prolonged administration of tedizolid: a review41
Emerging issues on Staphylococcus aureus endocarditis and the role in therapy of daptomycin plus fosfomycin39
The efficacy and safety of ceftolozane-tazobactam in the treatment of GNB infections: a systematic review and meta-analysis of clinical studies37
The emergence of Japanese encephalitis as a public health concern in New South Wales Australia36
Nontuberculous mycobacterial pulmonary disease and the potential role of SPR72035
Preventing healthcare-related infections among older adults: a focus on cross-transmission of antibiotic-resistant bacteria34
Tackling antimicrobial resistance in sub-Saharan Africa: challenges and opportunities for implementing the new people-centered WHO guidelines34
Recent updates in treating carbapenem-resistant infections in patients with hematological malignancies33
Response to: ‘letter to the editor: “A multifaceted strategy is needed to limit the over-the-counter sale of antimicrobials “’32
Difficile to treat: advanced management strategies in difficult to treat Clostridioides difficile infections31
Reemergence of monkeypox: prevention and management31
Can inhaled antifungals provide a viable solution for treatment-refractory pulmonary fungal infections?30
Decoding drug resistance in Mycobacterium tuberculosis complex: genetic insights and future challenges29
Current status of immunomodulatory therapies in adult sepsis patients: where do we stand?27
Treatment of vaginitis caused by non-albicans Candida species26
Hypoalbuminemia as a predictor of severe dengue: a systematic review and meta-analysis26
Identifying predictors of treatment failure with community-acquired pneumonia: an update26
Can Saccharomyces cerevisiae be used as a therapeutic agent for vulvovaginal candidiasis?26
Tineas caused by hedgehogs due to Trichophyton erinacei an ascending agent of dermatophytosis25
0.51317691802979